Abstract

During 2004-2008, I have primarily been using population-based approaches and assessed stored samples in exisiting large biobanks. From the beginning of 2009, I have started to develop novel treatment trials for myeloma patients and also I am in the process of developing new prospective patient studies for individuals affected with high-risk precursor disease. During early 2010, I predict that we will be able to enroll our first precursor patients for early intervention using targeted therapies. These studies will be based on rigorous correlative science aimed to better understand underlying biological mechanisms of tumor development. By taking these approaches, and by constantly developing and improving our concepts, I bevieve that we will be able to delay progression and ultimately cure patients from myeloma in the future. In parallel, we are in the process of developing a myeloma mouse model.
The aim of this effort is to develop a model for drug development and better understanding of disease mechanisms.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011205-01
Application #
7966214
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2009
Total Cost
$80,965
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Manasanch, Elisabet E; Kristinsson, Sigurdur Y; Landgren, Ola (2013) Etiology of Waldenstrom macroglobulinemia: genetic factors and immune-related conditions. Clin Lymphoma Myeloma Leuk 13:194-7
Kristinsson, Sigurdur Y; Eloranta, Sandra; Dickman, Paul W et al. (2013) Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 88:60-5
Drahos, Jennifer; Vanwormer, Jeffrey J; Greenlee, Robert T et al. (2013) Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol 23:291-3
Wu, S Peter; Minter, Alex; Costello, Rene et al. (2013) MGUS prevalence in an ethnically Chinese population in Hong Kong. Blood 121:2363-4
Shiels, Meredith S; Landgren, Ola; Goedert, James J et al. (2013) Reply to bibas et Al. Clin Infect Dis 56:1350
Engels, Eric A; Savoldo, Barbara; Pfeiffer, Ruth M et al. (2013) Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation 95:519-26
Katzmann, J A; Clark, R; Kyle, R A et al. (2013) Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 27:208-12
Auner, Holger W; Pavlu, Jiri; Szydlo, Richard et al. (2012) Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 157:125-7
Sjoberg, Jan; Halthur, Cat; Kristinsson, Sigurdur Y et al. (2012) Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 119:990-6
Birmann, Brenda M; Neuhouser, Marian L; Rosner, Bernard et al. (2012) Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 120:4929-37

Showing the most recent 10 out of 52 publications